• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4634701)   Today's Articles (2235)   Subscriber (49994)
For: Magliulo D, Wade SD, Kyttaris VC. Immunogenicity of SARS-CoV-2 vaccination in rituximab-treated patients: Effect of timing and immunologic parameters. Clin Immunol 2021;234:108897. [PMID: 34848357 PMCID: PMC8627008 DOI: 10.1016/j.clim.2021.108897] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Revised: 11/24/2021] [Accepted: 11/24/2021] [Indexed: 12/12/2022]
Number Cited by Other Article(s)
1
Degtiarova G, Conen A, Klarer A, Arifi T, Guldimann G, Finkener S, Spirig A, Kabitz HJ. Transfusion-related acute lung injury (TRALI) following intravenous immunoglobulin infusion in a rituximab immunosuppressed patient with long-shedding SARS-CoV-2. BMC Infect Dis 2024;24:916. [PMID: 39232646 PMCID: PMC11373488 DOI: 10.1186/s12879-024-09809-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2024] [Accepted: 08/26/2024] [Indexed: 09/06/2024]  Open
2
Romero-Bogado L, Steiner M, Thuissard Vasallo IJ, Andreu Vázquez C, Navío T, Muñoz-Fernández S. [Impact of systemic therapies on SARS-CoV-2 antibody seroprevalence in patients with immune-mediated diseases]. Med Clin (Barc) 2024;162:470-476. [PMID: 38418311 DOI: 10.1016/j.medcli.2023.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2023] [Revised: 12/02/2023] [Accepted: 12/05/2023] [Indexed: 03/01/2024]
3
Overbeck V, Taylor BP, Turcinovic J, Qiu X, Schaeffer B, Seitz S, Curry SR, Hanage WP, Connor JH, Kuppalli K. Successful treatment of SARS-CoV-2 in an immunocompromised patient with persistent infection for 245 days: A case report. Heliyon 2024;10:e23699. [PMID: 38223743 PMCID: PMC10784163 DOI: 10.1016/j.heliyon.2023.e23699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2023] [Revised: 12/08/2023] [Accepted: 12/11/2023] [Indexed: 01/16/2024]  Open
4
Urra JM, Castro P, Jiménez N, Moral E, Vozmediano C. Partial recovery of SARS-CoV-2 immunity after booster vaccination in renal transplant recipients. CLINICAL IMMUNOLOGY COMMUNICATIONS 2023;3:1-5. [PMID: 38014395 PMCID: PMC9741556 DOI: 10.1016/j.clicom.2022.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 11/11/2022] [Revised: 11/24/2022] [Accepted: 12/10/2022] [Indexed: 12/14/2022]
5
Vanni A, Salvati L, Mazzoni A, Lamacchia G, Capone M, Francalanci S, Kiros ST, Cosmi L, Puccini B, Ciceri M, Sordi B, Rossolini GM, Annunziato F, Maggi L, Liotta F. Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma-affected patients. Front Immunol 2023;14:1322594. [PMID: 38106404 PMCID: PMC10722279 DOI: 10.3389/fimmu.2023.1322594] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2023] [Accepted: 11/17/2023] [Indexed: 12/19/2023]  Open
6
Sciascia S, Rilat MLA, Fenoglio R, Foddai SG, Radin M, Cecchi I, Cinnirella G, Crosasso P, Guidetti MG, Barinotti A, Baldovino S, Menegatti E, Roccatello D. Safety and efficacy of pre-exposure prophylaxis with tixagevimab/cilgavimab (Evusheld) in patients with glomerular diseases who received rituximab. Clin Kidney J 2023;16:1465-1468. [PMID: 37664578 PMCID: PMC10469100 DOI: 10.1093/ckj/sfad111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Indexed: 09/05/2023]  Open
7
Ammitzbøll C, Kragh Thomsen M, Bøgh Andersen J, Jensen JMB, From Hermansen ML, Dahl Johannsen A, Larsen ML, Mistegaard CE, Mikkelsen S, Szabados F, Vils SR, Erikstrup C, Hauge EM, Troldborg A. Rituximab-treated rheumatic patients: B cells predict seroconversion after COVID-19 boost or revaccination in initial vaccine non-responders. Rheumatology (Oxford) 2023;62:2544-2549. [PMID: 36445008 DOI: 10.1093/rheumatology/keac666] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2022] [Accepted: 11/02/2022] [Indexed: 07/20/2023]  Open
8
del Pino Molina L, Bravo Gallego LY, Nozal P, Soto-Serrano Y, Martínez-Feito A, Reche-Yebra K, González-Torbay A, Cuesta-Martín de la Cámara R, Gianelli C, Cámara C, González-García J, González-Muñoz M, Rodríguez-Pena R, López Granados E. Detection of specific RBD+ IgG+ memory B cells by flow cytometry in healthcare workers and patients with inborn errors of immunity after BNT162b2 m RNA COVID-19 vaccination. Front Immunol 2023;14:1136308. [PMID: 37215146 PMCID: PMC10192857 DOI: 10.3389/fimmu.2023.1136308] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2023] [Accepted: 04/13/2023] [Indexed: 05/24/2023]  Open
9
Ocon AJ, Mustafa SS. Real-World Experience of Tixagevimab and Cilgavimab (Evusheld) in Rheumatologic Patients on Rituximab. J Clin Rheumatol 2023;29:109-111. [PMID: 36126256 DOI: 10.1097/rhu.0000000000001907] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
10
Alexopoulos H, Trougakos IP, Dimopoulos MA, Terpos E. Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies. Eur J Intern Med 2023;107:7-16. [PMID: 36379820 PMCID: PMC9647045 DOI: 10.1016/j.ejim.2022.11.009] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/25/2022] [Revised: 10/11/2022] [Accepted: 11/08/2022] [Indexed: 11/11/2022]
11
Hehir MK, Li Y. Diagnosis and Management of Myasthenia Gravis. Continuum (Minneap Minn) 2022;28:1615-1642. [PMID: 36537972 DOI: 10.1212/con.0000000000001161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
12
Troldborg A, Thomsen MK, Bartels LE, Andersen JB, Vils SR, Mistegaard CE, Johannsen AD, Hermansen MLF, Mikkelsen S, Erikstrup C, Hauge EM, Ammitzbøll C. Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases. J Rheumatol 2022;49:644-649. [PMID: 35232803 DOI: 10.3899/jrheum.211152] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/09/2022] [Indexed: 11/22/2022]
13
Lee ARYB, Wong SY, Tay SH. Booster COVID-19 Vaccines for Immune-Mediated Inflammatory Disease Patients: A Systematic Review and Meta-Analysis of Efficacy and Safety. Vaccines (Basel) 2022;10:668. [PMID: 35632424 PMCID: PMC9144569 DOI: 10.3390/vaccines10050668] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2022] [Revised: 04/17/2022] [Accepted: 04/18/2022] [Indexed: 01/29/2023]  Open
14
Bisceglia I, Canale ML, Gallucci G, Turazza FM, Lestuzzi C, Parrini I, Russo G, Maurea N, Quagliariello V, Oliva S, Di Fusco SA, Lucà F, Tarantini L, Trambaiolo P, Moreo A, Geraci G, Gabrielli D, Gulizia MM, Oliva F, Colivicchi F. Cardio-Oncology in the COVID Era (Co & Co): The Never Ending Story. Front Cardiovasc Med 2022;9:821193. [PMID: 35155636 PMCID: PMC8831543 DOI: 10.3389/fcvm.2022.821193] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 01/04/2022] [Indexed: 12/30/2022]  Open
15
Dai C, Dong ZY, Wang YN, Huang YH, Jiang M. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS 2022;114. [DOI: 10.17235/reed.2022.9264/2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA